A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd., London, England-Reference-Cited by-同舟云学术

A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd., London, England

Published:1998-01-20 Issue:2 Volume:9 Page:249-269
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Knowles Michael R.¹,Noone Peadar G.¹,Hohneker Kathy¹,Johnson Larry G.¹,Boucher Richard C.¹,Efthimiou John²,Crawford Catriona²,Brown Ronan²,Schwartzbach Caryl³,Pearlman Rodney⁴

Affiliation:

1. Cystic Fibrosis Centre, University of North Carolina at Chapel Hill, North Carolina, NC 27599

2. Glaxo Wellcome Research and Development Ltd, Greenford Road, London, England

3. Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, USA

4. Megabios Corp, Burlingame, California 94010, USA.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.1998.9.2-249

Reference12 articles.